<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">I Made Subhawa Harsa</style></author><author><style face="normal" font="default" size="100%">Andiani</style></author><author><style face="normal" font="default" size="100%">Sulistiawati</style></author><author><style face="normal" font="default" size="100%">Lilik Herawati</style></author><author><style face="normal" font="default" size="100%">Hanik Badriyah Hidayati</style></author><author><style face="normal" font="default" size="100%">Kuntaman</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">SCN9A and SCN10A Polymorphism and Therapeutic Effectiveness of Lidocaine Local Anesthetic Injection in Subjects with Diabetic Neuropathy Pain</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Diabetes</style></keyword><keyword><style  face="normal" font="default" size="100%">Diabetic neuropathy pain</style></keyword><keyword><style  face="normal" font="default" size="100%">Nav1.7</style></keyword><keyword><style  face="normal" font="default" size="100%">Nav1.8</style></keyword><keyword><style  face="normal" font="default" size="100%">Polymorphism</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">December 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">1259-1263</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Diabetic neuropathy pain (DNP) is one of the complications experienced by more than half of the diabetic population. Treatment using lidocaine injection is one of the effective ways to manage pain in patients with DNP. Pain therapy using lidocaine locally targets the SCN9A and SCN10A genes, which encode the sodium receptors Nav1.7 and Nav1.8. The effect of lidocaine inhibits these sodium channels to reduce pain transmission. &lt;strong&gt;Purpose:&lt;/strong&gt; This study aims to analyze the effect of polymorphism of genes encoding Nav1.7 and Nav1.8 on the effectiveness of lidocaine local injection therapy in patients with DNP. &lt;strong&gt;Methods:&lt;/strong&gt; This study was an analytic observational study with a cross-sectional approach. A total of 63 people with DNP were genotyped for the SCN9A rs 6746030 gene and the SCN10A rs12632942 gene using Real-Time PCR/qPCR and DNA sequencing. &lt;strong&gt;Result: &lt;/strong&gt;The results showed that 91.2% and 70.6% of the population who experienced decreased pain had the GA mutant allele in the SCN9A rs6746030 gene and the AG mutant allele in the SCN10A rs12632942 gene. The results showed a significant association of Nav1.7 and Nav1.8 gene polymorphisms with the effectiveness of lidocaine local anesthetic injection therapy in diabetic neuropathy pain patients (p &amp;lt; 0.05). &lt;strong&gt;Conclusion: &lt;/strong&gt;This study shows that there was an association between Nav1.7 and Nav1.8 gene polymorphisms and the effectiveness of lidocaine local anesthetic injection therapy in patients with DNP. Lidocaine injection therapy that targets the Nav1.7 and Nav1.8 sodium channels involving the SCN9A and SCN10A genes can be a therapeutic alternative for patients with DNP.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">1259</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;I Made Subhawa Harsa&lt;sup&gt;1,2&lt;/sup&gt;, Andiani&lt;sup&gt;1,3&lt;/sup&gt;, Sulistiawati&lt;sup&gt;4*&lt;/sup&gt;, Lilik Herawati&lt;sup&gt;5&lt;/sup&gt;, Hanik Badriyah Hidayati&lt;sup&gt;6&lt;/sup&gt;, Kuntaman&lt;sup&gt;7&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Doctoral Program of Medical Science, Faculty of Medicine, Universitas Airlangga, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Physiology, Faculty of Medicine, Wijaya Kusuma Surabaya University, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Public Health, Faculty of Medicine, Wijaya Kusuma Surabaya University, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Public Health and Preventive Medicine, Faculty of Medicine, Universitas Airlangga, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Department of Physiology, Faculty of Medicine, Universitas Airlangga, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;6&lt;/sup&gt;Department of Neurology, Faculty of Medicine, Universitas Airlangga, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;7&lt;/sup&gt;Department of Microbiology, Faculty of Medicine, Wijaya Kusuma Surabaya University, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Muhamad Robiul Fuadi</style></author><author><style face="normal" font="default" size="100%">Jusak Nugraha</style></author><author><style face="normal" font="default" size="100%">I Gde Rurus Suryawan</style></author><author><style face="normal" font="default" size="100%">Hartono Kahar</style></author><author><style face="normal" font="default" size="100%">Aryati</style></author><author><style face="normal" font="default" size="100%">Gwenny Ichsan Prabowo</style></author><author><style face="normal" font="default" size="100%">Budi Utomo</style></author><author><style face="normal" font="default" size="100%">Reny I’tishom</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Correlation of Apo E Gene Polymorphism with Recurrent Acute Coronary Syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Acute Coronary Syndrome</style></keyword><keyword><style  face="normal" font="default" size="100%">ApoE gene</style></keyword><keyword><style  face="normal" font="default" size="100%">PCR RFLP</style></keyword><keyword><style  face="normal" font="default" size="100%">Polymorphism</style></keyword><keyword><style  face="normal" font="default" size="100%">Public Health</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">450-453</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background&lt;/strong&gt;: Recurrent cardiovascular disease (CVD) incidence puts patients at higher risk for mortality and morbidity. One of the CVD symptoms is acute coronary syndrome (ACS). Many genetic polymorphisms are CVD risk factors. This study’s purpose was to investigate the correlation between recurrent ACS incidence and apolipoprotein E (ApoE) gene polymorphism.&lt;strong&gt; Method&lt;/strong&gt;: Case-control design was used in this study. About 90 patients who visited the cardiology and internal medicine clinics at UNAIR Hospital in Surabaya, Indonesia, served as the study's subjects. There were 30 patients with recurrent ACS, 30 patients with a single ACS, and 30 patients with no history of cardiovascular disease. Afterward, using the polymerase chain reaction-restriction fragment length method, the ApoE gene polymorphism examination was carried out. The Tropical Disease Center UNAIR Laboratory conducted all laboratory testing. R&lt;strong&gt;esults&lt;/strong&gt;: In the recurrent ACS group, ApoE polymorphism genotype patterns were 5 subjects for ε2ε2 (16.67%), 23 subjects for ε3ε3 (76.66%), and 2 subjects for ε4ε4 (6.67%). Meanwhile, in the single ACS group, ApoE polymorphism genotype patterns were 6 subjects for ε2ε2 (20%), 22 subjects for ε3ε3 (73.4%), 1 subject for ε4ε4 (3.33%), and 1 subject for ε2ε3 (3.33%). And, in the non- ACS group, ApoE polymorphism genotype patterns were4 subjects for ε2ε2 (13.34%), 25 subjects for ε3ε3 (83.33%), and1 subject for ε4ε4 (3.33%). There was no correlation of ApoE gene polymorphism with recurrent ACS incidence by Chi-square analysis (p &amp;gt; 0.05). &lt;strong&gt;Conclusion&lt;/strong&gt;: ApoE gene polymorphism cannot significantly affect recurrent ACS incidence.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">450</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Muhamad Robiul Fuadi&lt;sup&gt;1&lt;/sup&gt;, Jusak Nugraha&lt;sup&gt;2,*&lt;/sup&gt;, I Gde Rurus Suryawan&lt;sup&gt;3&lt;/sup&gt;, Hartono Kahar&lt;sup&gt;2&lt;/sup&gt;, Aryati&lt;sup&gt;2&lt;/sup&gt;, Gwenny Ichsan Prabowo&lt;sup&gt;4&lt;/sup&gt;, Budi Utomo&lt;sup&gt;5&lt;/sup&gt;, Reny I’tishom&lt;sup&gt;6&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Doctoral Program of Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Physiology and Medical Biochemistry, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Department of Public Health and Preventive Medicine Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;6&lt;/sup&gt;Department of Medical Biology, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Em Sutrisna</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Role of CYP3A4 and CYP2C8 Polymorphism on Amiodarone Responses: Review Article</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Amiodarone responses.</style></keyword><keyword><style  face="normal" font="default" size="100%">CYP2C8</style></keyword><keyword><style  face="normal" font="default" size="100%">CYP3A4</style></keyword><keyword><style  face="normal" font="default" size="100%">Polymorphism</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">467-470</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction&lt;/strong&gt;: Amiodarone is one of drug with narrow therapeutics index. This medicine was metabolized by CYP3A4 and CYP2C8. The changes in the activity of this enzymes by CYP3A4 and CYP2C8 polymorphism will affect the effect. The study aimed to determine the impact of CYP3A4 and CYP2C8 polymorphism on amiodarone responses.&lt;strong&gt; Method: &lt;/strong&gt;the study is review article with search article in PubMed with keywords: ‘amiodarone’ and ‘polymorphism of CYP3A4’ and ‘polymorphism of CYP2C8’. &lt;strong&gt;Results&lt;/strong&gt;: We collect 46 references to determine of impact polymorphism of CYP3A4 and CYP2C8 on amiodarone responses. &lt;strong&gt;Conclusion: &lt;/strong&gt;Individual with CYP3A4*22 (rs35599367, 15389C&amp;gt;T); CYP2C8*2 (A805T), CYP2C8*3 (G416A, A1196G), and CYP2C8*4 (C792G) and CYP2C8*4 polymorphism have lower activity of CYP3A4 and CYP2C8 enzymes and potentially cause adverse effect.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Review Article</style></work-type><section><style face="normal" font="default" size="100%">467</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Em sutrisna&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;Pharmacology laboratory of medical faculty of Universitas Muhammadiyah Surakarta, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>